Cyberpunk 2077 has sold a lot more copies than you think - and faster than The Witcher 3

CD Projekt reported that Cyberpunk 2077 has sold over 35 million copies, reaching that milestone faster than The Witcher 3 and is currently the studio's primary revenue driver as it expands availability across Switch 2, Mac and PlayStation Plus. The company said recent releases and platform adaptations helped lift earnings above levels seen around the Phantom Liberty expansion in 2023; CDPR is increasing staffing on sequels with 135 developers on Cyberpunk 2 and 447 on The Witcher 4, the latter also drawing strong consumer anticipation. These metrics indicate solid ongoing demand and a growing content pipeline that could support near-term revenue growth and investor confidence, though the news is incremental rather than market-moving.

Analysis

Market structure: CD Projekt (CDR.WA) emerging as a near-term winner — 35m Cyberpunk units and faster sell-through than Witcher 3 implies repeatable monetization and improved distribution (Switch 2, Mac, PS Plus) that should lift FY revenue by a material mid-single-digit to low-double-digit percent vs prior quarter over the next 3–12 months. Sony (SONY) sees ancillary benefit via higher platform engagement and subscription lift; Nvidia (NVDA) gets modest positive halo from tech-demo attention but no direct immediate hardware cycle catalyst. Expect pricing power for marquee AAA titles to remain intact; smaller studios face increased marketing spend to compete.

Risk assessment: Tail risks include development delays or a high-profile bug in Witcher 4 that could trigger a >30% sentiment hit to CDPR within 6–12 months and wider reputational contagion across European gaming stocks. Macro/consumer-spend squeeze or a failed platform deal (exclusive or subscription terms) within 0–6 months could compress margins; supply-side GPU shortages would affect NVDA upside. Hidden dependencies: platform revenue-share terms, live-service retention rates, and regional regulatory/lootbox scrutiny could change cash flow profiles over 12–36 months.

Trade implications: Tactical overweight CD Projekt for 3–12 months to capture franchise momentum and pre-marketing run-up for Witcher 4; modest long Sony exposure to collect platform upside; small, tactical NVDA options trade to capture GPU upside if marketing ramps. Use pair trades (long CDR.WA vs short EMBRAC-B.ST) to isolate IP strength. Time entries into CDR ahead of major industry events (The Game Awards, quarterly reports) and scale out on 20–35% rallies.

Contrarian angles: Consensus underestimates execution risk on sequels — Witcher 4’s large headcount (447) raises burn and QA burden; if cost overruns occur upside could be capped even with strong demand. The market may underprice subscription-margin dilution from placing big titles on PlayStation Plus; that could flip near-term revenue growth into longer-term ARPU pressure. Historical parallel: CDPR’s post-launch recovery of Cyberpunk shows operational resilience, but investors should not extrapolate linear gains without watching retention and DLC monetization metrics.

Key Decisions for Investors

• Establish a 2–3% net-long position in CD Projekt (CDR.WA) within the next 2–8 weeks; target +30–50% upside over 12 months, set a hard stop at -20% to limit execution/delay risk (reflects potential development setbacks).
• Initiate a 1–2% long position in Sony (SONY) or buy 9–12 month call options (10–15% OTM) sized to 1% notional to capture platform/subscription upside; trim on a 15–25% rally or after quarterly guidance beats.
• Buy a small, tactical NVDA 3–6 month call spread (e.g., 10%–20% OTM) sized to 0.5–1% of portfolio to play incremental GPU demand from next-gen title attention; cap max premium paid to <0.5% portfolio.
• Implement a relative-value pair: Long CDR.WA (2%) vs short EMBRAC-B.ST (1.5–2%) to hedge macro/genre risk and isolate IP execution; rebalance after material share moves (>15%) or after major product milestones.
• Use options for protection: buy 6–12 month 25% OTM protective puts on CDR.WA for 0.5% portfolio cost if you cannot tolerate a >20% drawdown from idiosyncratic release risk.